Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ARCT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults NCT06602531 · Influenza, Human ARCT-2304, Control vaccine younger adults | ARCT Arcturus Therapeutics, Inc. | Phase 1/2 | Completed | 212 | Jun 13, 2025 | Registry ↗ |
| May 8, 2026 | Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis NCT06747858 · Cystic Fibrosis, CFTR Gene Mutation ARCT-032 | ARCT Arcturus Therapeutics, Inc. | Phase 2 | Recruiting | 33 | Jun 2027 | Registry ↗ |
| Dec 12, 2025 | Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenz… NCT06279871 · COVID-19 ARCT-2303, Influenza vaccine | ARCT Arcturus Therapeutics, Inc. | Phase 3 | Completed | 1,514 | Oct 9, 2024 | Registry ↗ |
| Oct 15, 2025 | A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy A… NCT05037097 · COVID-19, SARS-CoV-2 Infection ARCT-165, ARCT-154 | ARCT Arcturus Therapeutics, Inc. | Phase 1/2 | Completed | 72 | Dec 19, 2023 | Registry ↗ |
| Oct 3, 2025 | Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influen… NCT06125691 · Influenza, Human ARCT-2138, Licensed Quadrivalent Vaccine for younger adults | ARCT Arcturus Therapeutics, Inc. | Phase 1 | Completed | 139 | Aug 10, 2024 | Registry ↗ |
| Sep 26, 2025 | Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and… NCT05526066 · Ornithine Transcarbamylase Deficiency, OTC Deficiency ARCT-810, Placebo | ARCT Arcturus Therapeutics, Inc. | Phase 2 | Terminated | 8 | Oct 31, 2024 | Registry ↗ |
| May 15, 2025 | A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults NCT04668339 · Covid19, SARS-CoV Infection ARCT-021 single dose priming, ARCT-021 two lower dose primi… | ARCT Arcturus Therapeutics, Inc. | Phase 2 | Terminated | 581 | Mar 1, 2022 | Registry ↗ |
| Mar 17, 2025 | A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD NCT06488313 · OTC Deficiency, Ornithine Transcarbamylase Deficiency ARCT-810 | ARCT Arcturus Therapeutics, Inc. | Phase 2 | Recruiting | 9 | Jun 1, 2026 | Registry ↗ |
| Dec 30, 2024 | Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021 NCT04728347 · SARS-CoV-2 ARCT-021 | ARCT Arcturus Therapeutics, Inc. | Phase 2 | Terminated | 65 | Dec 28, 2021 | Registry ↗ |
| Nov 13, 2024 | Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cy… NCT05712538 · Cystic Fibrosis ARCT-032, Placebo | ARCT Arcturus Therapeutics, Inc. | Phase 1 | Completed | 39 | Jul 29, 2024 | Registry ↗ |
| Aug 2, 2024 | Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Sub… NCT04442347 · Ornithine Transcarbamylase Deficiency ARCT-810, Placebo | ARCT Arcturus Therapeutics, Inc. | Phase 1 | Completed | 16 | Aug 30, 2023 | Registry ↗ |
| Nov 8, 2023 | Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects NCT04416126 · Ornithine Transcarbamylase Deficiency ARCT-810, Placebo | ARCT Arcturus Therapeutics, Inc. | Phase 1 | Completed | 30 | Dec 9, 2020 | Registry ↗ |
| Aug 18, 2021 | Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects NCT04480957 · SARS-CoV-2 ARCT-021 Dose 1, ARCT-021 Dose 2 | ARCT Arcturus Therapeutics, Inc. | Phase 1/2 | Completed | 106 | Jan 29, 2021 | Registry ↗ |
13 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances